INmune Bio Stock Forecast
NASDAQ: INMBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 1:48 PM ET
INMB analyst consensus
Consensus (3 analysts)
strong_buy
Avg. price target
$7.00+277.36%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 3 Wall Street analysts covering INmune Bio (2026-10-09), 3 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $7.00, with a high estimate of $9.00 and a low estimate of $4.00. The average target implies upside of 277.4% from the current price of $1.86.
The spread between the highest and lowest targets is 125.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for INMB.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 33% |
| Buy | 2 | 67% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $4.00 | +115.63% |
| Average target | $7.00 | +277.36% |
| High target | $9.00 | +385.18% |